Chinese fine chemicals manufacturer Huadao Biopharma announced last week the completion of a series B round of financing worth RMB100 million (US$14.18 million) led by Shenzhen-listed chemicals developer NKY Medical Holdings.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
